1 pahu (10 Vials)
| Loaʻa: | |
|---|---|
| Ka nui: | |
▎ He aha ka Vilon?
ʻO Vilon, kahi dipeptide i haku ʻia me ka lysine a me ka glutamic acid, hōʻike i nā hopena multifaceted. I ka anti-aging, hoʻopaneʻe ia i ka ʻelemakule cellular ma o ka hoʻomaikaʻi ʻana i ka hana o ka gastrointestinal, hoʻonui i ka hana enzyme, a me ka hoʻoikaika ʻana i ka lawe ʻana i nā meaʻai. Hoʻonui ia i ka hōʻike collagen i ka ʻili e hōʻemi i nā hōʻailona o ka ʻelemakule. Ma ka hoʻoponopono a me ka hana hou ʻana o ka ʻiʻo, kākoʻo ʻo Vilon i ka hoʻōla ʻana a me ka hoʻonui ʻana o ka cell cell, hoʻolalelale i ka hoʻōla ʻana i ka ʻeha, a kōkua i ka hoʻoponopono ʻana i ka ʻiʻo (e laʻa, ka ʻili a me nā ʻiʻo ʻōpū) ma o ka hoʻoponopono ʻana i ka hana fibroblast. Maikaʻi no ke olakino cardiovascular a me ka renal, hoʻomaikaʻi ia i ka hana cardiovascular a hoʻoponopono i ka microvascular permeability i nā maʻi renal. Hoʻohui hou, hōʻike ʻo Vilon i nā noi kūpono i ka adjuvant therapy no nā maʻi ate, ka maʻi diabetes, a me nā hōʻeha radiation, a me ka hoʻoponopono ʻana i nā hana holoʻokoʻa o ke kino.
▎ Hoʻolālā Vilon
Puna: PubChem |
Sequence: KE Hui Molekala: C 11H 21N 3O5 Kaumaha Molekala: 275.30g/mol Helu CAS: 45234-02-4 PubChem CID: 7010502 Synonyms: lysylglutamic acid |
▎ ʻImi Vilon
He aha ke kumu noiʻi o Vilon?
1. ʻO ka makemake wikiwiki no ka noiʻi ʻana i ka ʻelemakule a me nā maʻi
Me ka wikiwiki o ke kaʻina hana ʻelemakule o ka honua, ua lilo nā ʻano pilikia e pili ana i ka ʻelemakule, e like me ka senescence cellular, ka emi ʻana o ka hana o ke kino, a me ka nui o nā maʻi geriatric, ua lilo i mau pilikia olakino e hoʻoponopono ʻia. Hoʻopili pū ʻia ka senescence kelepona me ka nalowale lohi o ka hiki ke mālama i ka homeostasis a hoʻoponopono i nā ʻiʻo i hōʻino ʻia, no laila he mea koʻikoʻi loa ka loaʻa ʻana o nā mea hiki ke hoʻopaneʻe i ke kaʻina o ka senescence cellular a hoʻomaikaʻi i ka hana hoʻoponopono kino.
I ka manawa like, hoʻoweliweli koʻikoʻi nā maʻi nui e like me ke kanesa, ka maʻi diabetes, nā maʻi cardiovascular, a me nā maʻi ate i ke olakino kanaka. Loaʻa i nā ʻano lapaʻau kuʻuna kekahi mau palena i ka hoʻoponopono ʻana i kēia mau maʻi, a he mea nui e hoʻomohala i nā ʻano lapaʻau hou a me nā lāʻau lapaʻau. No ka laʻana, ʻaʻole ʻoluʻolu nā poʻe maʻi maʻi maʻi ʻelemakule i ka radiotherapy a me ka chemotherapy, a ʻaʻole ʻoluʻolu ka hopena o ka mālama ʻana. He mea koʻikoʻi ka loaʻa ʻana o nā ʻano lapaʻau adjuvant palekana a maikaʻi. I loko o ia kūlana paʻakikī, ua huli ka poʻe ʻepekema i ko lākou manaʻo i nā peptides bioactive, me ka manaʻo e loaʻa kahi wahi holomua, a ua hoʻomaka ka noiʻi ʻana ma Vilon.
2. ʻO ka hoʻomohala ikaika ʻana o ka noiʻi ʻana ma Bioactive Peptides
Nui nā mea peptide i loko o nā mea ola a komo i nā kaʻina hana physiological koʻikoʻi, e like me ka hōʻailona cell, ka hoʻoponopono immune, a me ka hoʻoponopono metabolic. I nā makahiki i hala iho nei, me ka hoʻomohala wikiwiki ʻana o nā ʻenehana e like me ka biology molecular a me ka biochemistry, ua holomua nui i ka noiʻi ʻana i nā peptides bioactive.
Hiki i nā kānaka ʻepekema ke hoʻohui pololei, hoʻokaʻawale, a ʻike i nā peptides like ʻole, a ʻimi hohonu i kā lākou mau hana. Ua hōʻike ka nui o nā haʻawina i nā peptides me nā ʻano hana like ʻole i nā hana olaola like ʻole, e lawe mai ana i ka manaʻolana hou no ka hoʻoponopono ʻana i nā pilikia olakino a me nā maʻi. Ma kēia kaʻina hana, ua aʻo nā mea noiʻi i ka nui o nā peptides ma o nā ʻano e like me ke kiʻekiʻe-throughput screening a me ka hōʻoia hana. ʻO Vilon, ma ke ʻano he dipeptide me kahi ʻano kūʻokoʻa a me nā hana kūpono, ua hele mālie i ka ʻike o ka poʻe.
3. Ka 'Imi Hohonu o ka Mechanisms of Tissue Repair and Regeneration
ʻO ka hoʻoponopono a me ka hoʻoponopono houʻana he mau hana koʻikoʻi no ka mālamaʻana i nā hana physiological maʻamau o nā meaola a me ka paneʻana i nāʻeha. Eia nō naʻe, he nui nā hakahaka o ka ʻike o kēia kaʻina hana, a ʻo ke ʻano o ka hoʻoikaika ʻana i ka hoʻoponopono ʻana a me ka hoʻoponopono hou ʻana i nā kiko i lilo i mea nui o ka noiʻi. He koʻikoʻi ko nā pūnaewele puʻupuʻu i ka hoʻoponopono ʻana a me ka hana hou ʻana o ka ʻiʻo, a ʻo ka noiʻi ʻana e pili ana i kā lākou hoʻāla ʻana, hoʻonui, a me nā ʻano hana ʻokoʻa ua loaʻa ka nānā nui ʻana.
Eia kekahi,ʻo nā mea e like me ka synthesis a me ka hoʻohaʻahaʻaʻana o ka matrix extracellular a me ka hōʻailona intercellular he hopena koʻikoʻi hoʻi i ka hoʻoponopono kino. I ke kaʻina o ka ʻimi ʻana i nā hana o ka hoʻoponopono ʻana a me ka hana hou ʻana, ua ʻike nā mea noiʻi hiki i kekahi mau peptides ke hoʻoponopono i kēia mau kaʻina hana. Ma muli o kēia, ua hoʻomau mau ʻia ka noiʻi ʻana i nā peptides me ka hiki ke hoʻoponopono i ka hoʻoponopono ʻana a me ka hana hou ʻana. Ua lilo ʻo Vilon i mea noiʻi koʻikoʻi ma kēia kahua ma muli o kāna mau hopena i ke kākoʻo ʻana i ka hoʻoulu ʻana o ka cell stem a me ka hoʻonui ʻana a me ka hoʻoponopono ʻana i ka hana fibroblast.
He aha ke ʻano o ka hana a Vilon?
1. Nā hopena ma nā Chromosomes a me Gene Expression
Hoʻoikaika i ka wehe ʻana o Heterochromatin: Ua hōʻike nā haʻawina e hiki i ka Vilon ke hoʻoulu i ka wehe ʻana (deheterochromatization) o ka heterochromatin holoʻokoʻa i loko o nā lymphocytes moʻomeheu o ka poʻe ʻelemakule [1] . ʻO ia ke ʻano hiki iā ia ke hoʻāla i ke kaʻina hana synthesis o nā genes ribosomal i hoʻokumu ʻia e ka deheterochromatization o ka nucleolar organizing region a hoʻokuʻu i nā genes i kāohi ʻia ma muli o ka condensation o ka ʻāina euchromatin e hana i ka heterochromatin facultative. I ka manawa like, ʻaʻole ʻo Vilon ke kumu i ka wehe ʻana o ka heterochromatin constitutive a puni ka centromere. Hōʻike nā hualoaʻa e hoʻōla mālie ʻo Vilon i ka heterochromatin facultative (deheterochromatization) me ka makahiki [1].
2. Nā kuleana i ka mālama ʻana i ka maʻi
Hoʻomaʻamaʻa piha no nā maʻi maʻi maʻi maʻi: I ka mālama ʻana i nā poʻe maʻi maʻi maʻi ʻelemakule, ua hoʻokomo ʻia ʻo Vilon i ka hoʻolālā lapaʻau ma ke ʻano he immunomodulator. Hōʻike nā hopena noiʻi mua e hiki i ka hoʻohana ʻana iā Vilon ke hoʻomaikaʻi i ka helu ola o 2 mau makahiki o nā maʻi, pale i nā hoʻopiʻi postoperative, nā pilikia mamao, ka hoʻihoʻi hou ʻana, a me ka laha ʻana o ka maʻi tumora, a hoʻomaikaʻi i ka maikaʻi o ke ola ma hope o ka mālama ʻana [2].
Antitumor Effect: In vitro hoʻokolohua, Vilon i ka maʻiʻaʻai-pili inhibitory hopena ma luna o ka ulu o ekolu ano o ka maʻi 'aʻai maʻi 'aʻai LOVO, kanaka gastric maʻi 'aʻai MKN45, a me kanaka ake maʻi 'aʻai QGY7703, akā, 'aʻohe maopopo inhibitory hopena ma ke kanaka maʻamau keʻokeʻo koko [3] . Ua hōʻike ʻia nā hoʻokolohua hoʻāʻo ʻana i ka maʻi maʻi ma vivo he hopena pale ka Vilon i ka ulu ʻana o ka maʻi ʻaʻai ate ʻiole H22, a ʻo ka nui o ka hopena he 15mg・Kg-1. Ke hoʻohana ʻia ka nui kiʻekiʻe o 30mg・Kg-1, ʻoi aku ka nui o ka pale ʻana o ka maʻi ʻaʻai maʻi ʻaʻai ʻo H22 i nā ʻiole ma mua o 60% [3].
Nā hopena i nā maʻi maʻi maʻi: I nā poʻe maʻi maʻi maʻi maʻi ʻano I, ʻo Vilon, ma ke ʻano he ʻāpana o ka mālama piha ʻana, hiki ke hoʻonui i ka hana coagulation a me ka hemostasis, i hōʻike ʻia e like me ka hoʻonui ʻana i ka ʻike o nā anticoagulants kūlohelohe (antithrombin III a me ka protein C) a me ka hoʻoulu ʻana o fibrinolysis [4] . I ka manawa like, i ka hapanui o nā hihia, hiki iā Vilon ke hōʻemi i ka nui o ka insulin i koi ʻia e hoʻopaʻa i ka metabolism carbohydrate. Eia kekahi, hiki iā ia ke hōʻemi i ka ʻike o nā mea kōkua T, T-dependent a me ka ʻole o T-dependent NK cell, hoʻomaʻamaʻa i nā pae o nā lymphocytes T ikaika, B lymphocytes, a me IgA, a he hopena stabilizing i ka ʻōnaehana immune a me ka hana hemostasis [4].
3. Nā hopena ma nā hana kelepona a me nā mea kino
Hoʻoulu hou i ka Hepatocyte: Ma kahi ʻano ʻiole o ka ate cirrhosis i hoʻoulu ʻia e ka carbon tetrachloride poisoning, he hopena ko Vilon i ka hoʻihoʻi ʻana i ka hana hana o nā hepatocytes a me ka hana hou ʻana o ke ake i nā ʻiole me ka cirrhosis ate. ʻElua pule ma hope o ka hoʻohana ʻana i ka lāʻau lapaʻau, e emi ana ka hana o ka glucose-6-phosphatase (G6P) i loko o ke ake o nā ʻiole me ka cirrhosis ate, a hiki iā Vilon ke hoʻonui. I nā ʻiole i mālama ʻole ʻia, aia nō ka ʻike o ka glycogen a me kāna mau ʻāpana a me ka hana o G6P i ka pae pre-cirrhosis. I loko o ka hoʻokolohua holoʻokoʻa, ʻaʻohe ʻokoʻa nā hana o ka glycogen phosphorylase (GP) a me ka glycogen synthase (GS) i loko o ke ake o nā ʻiole me ka cirrhosis ate ma nā pūʻulu ʻelua mai nā waiwai hoʻomalu. ʻO Vilon kahi hopena hoʻoulu nāwaliwali i ka hana hou ʻana o ke ake i nā ʻiole me ka cirrhosis ate, i hōʻike ʻia e like me ka nui o ka protein a me ka pae ploidy i loko o nā hepatocytes o ka lua o nā ʻiole he 4.7% a me 11.5% kiʻekiʻe ma mua o ka hui mua [5].
Nā hopena i nā ʻāpana Radiosensitive: Hoʻoulu ʻo Vilon i ka hana proliferative o nā thymocytes a hoʻonui i ka mana proliferative o nā pūnaewele ʻōpū o ka ʻōpū, ma laila e hoʻoulu ai i ka hoʻihoʻi hou ʻana o nā ʻāpana kī. No ka laʻana, ua ʻike nā haʻawina e pili ana i nā ʻiole paʻa a me nā ʻiole i loaʻa i ke kino holoʻokoʻa gamma-ray irradiation (6Gy) he hopena ko Vilon i ka morphology hana o ka thymus, spleen, a me duodenum [6].
4. Nā kuleana ma ka pae Molecular
Mechanism hiki ke hoʻopaʻa i ka Membrane: Ua hōʻike ʻia nā haʻawina trajectory molecular dynamics ʻo Vilon (lysylglutamic acid dipeptide) a me thymopoietin (Glu-Trp) i loaʻa nā alahaka paʻakai intramolecular i kā lākou mau hale, e hōʻemi ana i kā lākou conformational flexibility. Ma muli o ke kaulahao ʻaoʻao aliphatic o Lys, ʻoi aku ka maʻalahi o Vilon. Ua manaʻo ʻia kahi mea hiki ke hoʻopaʻa ʻia i ka ligand-receptor o ka dipeptide i ka membrane excitable, ʻo ia hoʻi, ka hoʻopaʻa ʻana ma o ka nitrogen a me ka oxygen atom e hana i ke alahaka paʻakai [7].
Nā hopena ma ka Protein Expression i ka Nucleolar Organizing Region: Vilon hoʻoulu a keʻakeʻa i ka hōʻike ʻana o nā protein AIDS i nā ʻāpana hoʻonohonoho nucleolar o ka ʻiʻo serum a me ka nuclei cell epithelial, e hana ana a hōʻemi paha i ka hoʻokumu ʻana, hui ʻana, a me ka lawe ʻana o nā ribosomes i ka cytoplasm, pēlā e hoʻoholo ai i ka ikaika o ka synthesis protein. Eia kekahi, hoʻolaha kēia peptide i ka hoʻololi ʻana o nā thymocytes i loko o nā pūnaewele blast proliferating [8].
He aha nā mea hoʻohana o Vilon?
1. Anti-kahiko
Ua manaʻo ʻia ʻo Vilon he peptide anti-aging hiki ke hoʻopaneʻe i ka senescence cellular ma o ka hoʻomaikaʻi ʻana i ka hana o ka ʻōpū, hoʻonui i ka hana enzyme, a me ka hoʻoikaika ʻana i ka hoʻohana ʻana i ka meaʻai. Eia kekahi, ua ʻike ʻia ʻo Vilon e hiki ke hoʻomaikaʻi i ka hōʻike ʻana o ka collagen ʻili a hoʻemi i nā hōʻailona o ka ʻelemakule ʻili. Uaʻike nā haʻawina e hiki i ka peptide KE (Lys-Glu, Vilon) ke hoʻonui i ka'āpana hōʻike o ka collagen 1 i ka moʻomeheu o nā fibroblastsʻili senescent e 83%; Hoʻonui ia i ka ʻāpana hōʻike o sirtuin 6 i ka moʻomeheu o nā ʻili fibroblasts ʻōpio a ʻelemakule e 1.6 a me 2.6 mau manawa [11].
2. Hoʻoponopono a me ka hana hou ʻana o ka Tissue
Hōʻike ʻo Vilon i ka mana koʻikoʻi i ka hoʻoponopono ʻana a me ka hana hou ʻana. Hiki iā ia ke kākoʻo i ka hoʻoulu ʻana a me ka hoʻonui ʻana o nā pūnaewele stem, e hoʻolalelale i ka hōʻeha ʻeha a me ka hoʻoponopono ʻana i ka ʻiʻo. Ua ʻike pū ʻia nā haʻawina e hiki i ka Vilon ke hoʻoikaika i ka hoʻoponopono ʻana i ka ʻili, nā ʻōpū, a me nā ʻiʻo ʻē aʻe ma o ka hoʻoponopono ʻana i ka hana fibroblast. Ua hōʻike ʻia nā haʻawina ua hoʻohui ʻia ka synthetic dipeptide Vilon i ka moʻomeheu explant mai nā ʻiole o nā makahiki like ʻole. Ua hōʻike nā hopena i hiki iā Vilon ke hoʻoulu i ka paʻa o ka morphological tissue, hoʻāla i ka hana hou a me ka hana hana o nā cell, a ua ʻoi aku ka ikaika o ka hopena i nā explants o nā ʻiole kahiko, e hōʻike ana he hiki ke hoʻoponopono ʻia ʻo Vilon [9].
3. Ka mālama ʻana i ka maʻi cardiovascular a me ka Renal
He hopena maikaʻi ka Vilon i ke olakino cardiovascular a me ka renal. Hiki iā ia ke hoʻomaikaʻi i ka hana cardiovascular ma o ka hoʻololi ʻana i ke ʻano hōʻike gene a hoʻonui i ka microvascular permeability i nā maʻi kīkī, e hāpai ana i ka hoʻonui ʻana i ka coagulation koko.
4. Nā noi i ka maʻi maʻi maʻi
Hoʻomaʻamaʻa piha no nā poʻe maʻi maʻi maʻi ʻelemakule: I ka mālama ʻana i nā poʻe maʻi maʻi maʻi ʻelemakule, ua hoʻokomo ʻia ʻo Vilon i ka hoʻolālā lapaʻau ma ke ʻano he immunomodulator. No ka laʻana, i ka hoʻomaʻamaʻa piha ʻana i nā poʻe maʻi maʻi me ka maʻi ʻaʻai rectal a me ka maʻi ʻaʻai kolonā, nā hopena noiʻi mua e hōʻike ana i ka noi ʻana o Vilon hiki ke hoʻomaikaʻi i ka helu ola o 2-makahiki o nā maʻi, pale i nā hoʻopiʻi postoperative, nā hoʻopiʻi mamao, hoʻi hou, a me ka laha ʻana o ka maʻi maʻi [2].
ʻO ka Stratification maʻi no nā maʻi maʻi he nui: ʻO ka ʻokoʻa o ka ʻike i hoʻohui ʻia ʻo Layers of Networks algorithm (ViLoN) i hāpai ʻia e Vilon he ʻano hana pūnaewele hou e hiki ke hoʻohana ʻia no ka hoʻohui ʻana i nā palapala ʻāina molekala. Ma ke ʻano o ka stratification o ka maʻi, ua hōʻoia ʻia kēia ʻano ma nā hui like ʻole o nā ʻano ʻikepili (gene expression, methylation, kope helu), a he hopena koʻikoʻi ka hoʻomaikaʻi ʻana i ka stratification maʻi, a loaʻa ka hoʻokūkū paʻa i nā hihia āpau. Ma nā pūʻulu liʻiliʻi (rectal adenocarcinoma: 90 hihia, esophageal cancer: 180 hihia), hoʻokomo i ka ʻike hana mua (KEGG, GO) he mea koʻikoʻi no ka loaʻa ʻana o nā hopena maikaʻi [10].
5. No ka Lapaau ana i na ma'i ate
Nā hopena i ke ake o nā ʻiole me ka ate Cirrhosis: Ua aʻo ʻia nā hopena o ka hoʻomākaukau ʻana o dipeptide 'Vilon' i ka hoʻihoʻi ʻana i ka hana hana o nā hepatocytes a me ka hana hou ʻana o ke ake i nā ʻiole me ka cirrhosis ate. ʻO nā ʻiole me ka ate cirrhosis i hoʻoulu ʻia e ka lāʻau ʻawaʻawa carbon tetrachloride no 4 mau mahina ua hāʻawi ʻia iā Vilon (1.7 micrograms/kg) a hoʻopaʻa ʻia i kēlā me kēia lā no 5 mau lā. Ua hōʻike nā hopena i ʻelua pule ma hope o ka hoʻohana ʻana i ka lāʻau lapaʻau, ua hoʻonui ʻia ka hana o ka glucose-6-phosphatase (G6P), i hoʻemi ʻia e 1.2 mau manawa i ka cirrhosis ate, ma lalo o ka hana a Vilon. ʻO Vilon kahi hopena hoʻoulu nāwaliwali i ka hana hou ʻana o ke ake i nā ʻiole me ka cirrhosis ate, i hōʻike ʻia e like me ka nui o ka protein a me ka pae ploidy i loko o nā hepatocytes o ka lua o nā ʻiole he 4.7% a me 11.5% kiʻekiʻe ma mua o ka hui mua [5].
6. Nā noi no ka mālama ʻana i ka maʻi diabetes
Nā hopena i ka poʻe maʻi maʻi maʻi ʻelemakule: ʻO Vilon, ma ke ʻano he thymic mimetic, ua hoʻohana ʻia ma ke ʻano he lāʻau adjuvant i ka mālama piha ʻana i nā poʻe maʻi maʻi diabetes type I. Hōʻike nā hopena i ka hoʻohana ʻana o Vilon i ka hana coagulation a me ka hemostasis, i hōʻike ʻia e like me ka hoʻonui ʻana i ka ʻike o nā anticoagulants kūlohelohe (antithrombin III a me ka protein C) a me ka hoʻoulu ʻana o ka fibrinolysis. I ka hapanui o nā hihia, hoʻemi ʻo Vilon i ka nui o ka insulin i koi ʻia e hoʻopaʻa i ka metabolism carbohydrate. I ka manawa like, hoʻemi ʻo Vilon i ka ʻike o nā cell helper T, T-dependent a me ka non-T-dependent NK cell, a hoʻomaʻamaʻa i nā pae o nā lymphocytes T ikaika, B lymphocytes, a me IgA, e hōʻike ana he hopena stabilizing ʻo Vilon i ka ʻōnaehana immune a me ka hana hemostasis [4].
7. Nā noi no ka mālama ʻana i ka ʻeha Radiation
Nā hopena ma nā ʻāpana Radiosensitive: Ua aʻo ʻia nā hopena o ka vilon a me ka epithalon ma ka morphology hana o ka thymus, spleen, a me ka duodenum o nā ʻiole paʻa a me nā ʻiole i loaʻa i ka hoʻoheheʻe γ-ray kino holoʻokoʻa o 6Gy. Hōʻike nā hopena i ka hoʻoulu ʻana o ka vilon i ka hana proliferative o nā thymocytes a hoʻonui i ka hiki ke hoʻonui ʻia o nā ʻōpū ʻōpū o ka ʻōpū, a laila e hoʻoulu ai i ka hoʻihoʻi hou ʻana o ka hoʻihoʻi ʻana o nā kino kī [6].
I ka hopena, ma ke ʻano he dipeptide kūikawā, hiki iā Vilon ke hoʻomaikaʻi i ka hana o ka ʻōpū, hoʻopaneʻe i ka ʻelemakule, kōkua i ka hoʻoponopono ʻana a me ka hoʻoponopono hou ʻana, a mālama i ke olakino cardiovascular a me renal. He hopena maikaʻi hoʻi ia i ka mālama ʻana i ka maʻi kanesa, nā maʻi ate, ka maʻi diabetes, a me nā ʻeha radiation.
No ka mea kakau
ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.
ʻO ka mea kākau moʻolelo ʻepekema ʻo Kańduła MM he mea noiʻi me nā pili i kekahi mau ʻoihana hanohano, me Janssen Pharmaceuticals, BOKU University, BOKU Vienna, Boston University, a me Johannes Kepler University Linz. ʻO kāna noiʻi ʻana i kahi ākea o nā kahua, e hōʻike ana i kāna ʻike interdisciplinary. Ma Biochemistry & Molecular Biology, ua kōkua ʻo ia i ka holomua ʻana i ka hoʻomaopopo ʻana i nā kaʻina cellular a me nā pilina molecular.
ʻO kāna hana ma Cell Biology e pili ana i ke aʻo ʻana i ke ʻano a me ka hana o nā cell, he mea koʻikoʻi ia no ka hoʻomohala ʻana i nā hoʻolālā therapeutic hou. Ma Biotechnology & Applied Microbiology, ua ʻimi ʻo Kańduła MM i nā ʻano hana hou no ka hoʻohana ʻana i nā ʻōnaehana microbial e hoʻoponopono i nā pilikia kūpono. ʻO kāna noiʻi ʻana ma Life Science & Biomedicine - Nā kumuhana ʻē aʻe e hōʻike ana i kona hoʻopili ʻana me nā ʻano hana ʻoki a me nā ʻenehana i ʻoi aku ma mua o nā palena ʻepekema kuʻuna. Eia kekahi, hōʻike kāna hana ma Engineering i kona hiki ke hoʻopili i nā loina ʻepekema i nā noi kūpono. Ma o kāna noiʻi multifaceted, ua hāʻawi ʻo Kańduła MM i nā haʻawina koʻikoʻi i ke kaiāulu ʻepekema, e hoʻoikaika ana i nā holomua theoretical a me nā noi kūpono i ka lāʻau lapaʻau a me ka biology. Ua helu ʻia ʻo Kańduła MM ma ka ʻōlelo kuhikuhi [10].
▎ Nā ʻōlelo pili
[1] Lezhava T, Khavison V, Monaselidze J, et al. ʻO ka bioregulator Vilon ka hoʻoulu hou ʻana o chromatin i nā lymphocytes moʻomeheu mai ka poʻe kahiko [J]. Biogerontology, 2004,5(2):73-79.DOI:10.1023/B:BGEN.0000025070.90330.7f.
[2] Ias'Kevich LS, Krutilina NI, Kostetskaia TV, et al. Hoʻohana ʻia o ka peptide bioregulator i ka mālama paʻakikī o nā maʻi maʻi maʻi ʻelemakule.[J]. Nā holomua ma Gerontology = Uspekhi Gerontologii, 2005,16:97-100. https://pubmed.ncbi.nlm.nih.gov/16075684/.
[3] Jun-hui C. Antitumor hana o Vilon dipeptide Lys-Glu[J]. Pākē Pharmacological Bulletin, 2007. https://api.semanticscholar.org/CorpusID:86988257.
[4] Bi K, Nv I, Nn K, et al. Ka hopena o ka vilon i ke kūlana palekana a me ka hemostasis coagulation i nā maʻi o nā makahiki like ʻole me ka maʻi diabetes [J]. Nā holomua ma Gerontology, 2007,20:106. https://pubmed.ncbi.nlm.nih.gov/18306698/.
[5] Kudriavtseva MV, Bezborodkina NN, Sek EN, et al. Ka hopena o ka 'vilon' ma ke ake o ka iole i ho'ololi 'ia. ʻO ka hana hou ʻana o ke ake, a me ke kūlana o ka hana hana glycogen o nā hepatocytes.[J]. Tsitologiia, 2000,42(8):758-764. https://pubmed.ncbi.nlm.nih.gov/11033862/.
[6] Khavinson VK, Yuzhakov VV, Kvetnoi IM, et al. Immunohistochemical a me morphometric ka nānā ʻana o nā hopena o ka vilon a me ka epithalon ma ka morphology hana o nā mea radiosensitive [J]. Bulletin of Experimental Biology and Medicine, 2001,131(3):285-292.DOI:10.1023/A:10 17676104877 .
[7] Shchegolev BF, Rogachevskii IV, Khavinson VK, et al. Hoʻonaʻauao Molecular Mechanics o ka Steric Structure o nā Dipeptides Vilon a me Thymogen[J]. ʻO Russian Journal of General Chemistry, 2003,73(12):1909-1913.DOI:10.1023/B:RUGC.0000025152.01400.52.
[8] Raikhlin NT, Bukaeva IA, Smirnova EA, et al. Hōʻike i nā protein argyrophilic i loko o nā ʻāpana hoʻonohonoho nucleolar o nā thymocytes kanaka a me nā epitheliocytes thymic ma lalo o nā kūlana o ka coculturing me Vilon a me Epithalon peptides [J]. Bulletin of Experimental Biology and Medicine, 2004,137(6):588-591.DOI:10.1023/B:BEBM.0000042720.40439.16.
[9] Kniaz'Kin IV, Iuzhakov VV, Chalisova NI, et al. ʻO ka morphology hana o ka moʻomeheu organotypic o nā spleens mai nā ʻiole o nā makahiki like ʻole i ʻike ʻia i ka vilon[J]. Nā holomua ma Gerontology, 2002,9:110-115. https://pubmed.ncbi.nlm.nih.gov/12096432/.
[10] Kańduła MM, Aldoshin AD, Singh S, et al. ʻO ViLoN-he ala hoʻopili pūnaewele nui i ka hoʻohui ʻikepili i hōʻike ʻia no ka stratification maʻi [J]. Nucleic Acids Research, 2023,51(1):e6.DOI:10.1093/nar/gkac988.
[11] Fridman NV, Linkova NS, Polyakova VO, et al. Nā ʻano Molecular o ka hopena Geroprotective o Peptide KE i loko o nā Fibroblasts ʻili kanaka [J]. Nā holomua ma Gerontology, 2018,8(3):235-238.DOI:10.1134/S2079057018030050.
ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.
ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a i ʻole maʻi. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.